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Background: Heterotaxy is a relatively uncommon congenital anomaly that is usually diagnosed incidentally on
imaging studies in adults. We present an unusual case of venous thromboembolism in a 26 year old pregnant
female with Heterotaxy syndrome.
Case presentation: A 26 year-old pregnant female at 13 weeks gestation suffered cardiac arrest with successful
cardiac resuscitation and return of spontaneous circulation. The cardiac arrest was secondary to massive pulmonary
embolism requiring thrombolytic therapy and stabilization of hemodynamics. She had extensive evaluation to
determine the etiology for the pulmonary embolism and was noted to have an anatomic variation consistent
with heterotaxy syndrome on imaging studies. After thrombolysis the patient was treated with UFH and then
switched to enoxaparin without complication until 25 weeks of gestation when she experienced worsening
abdominal pain with associated headaches, lightheadedness and elevated blood pressures needing elective induction of
labor. The infant died shortly after delivery. The anticoagulation was continued for additional 3 months and she
was subsequently placed on low dose aspirin to prevent recurrent venous thromboembolic episodes. She is currently
stable on low dose aspirin and is into her third year after the venous thromboembolism without any recurrence.
Conclusion: To our knowledge, this is the first reported case of venous thromboembolism in pregnancy associated with
heterotaxy syndrome. A discussion on pathophysiology of venous thromboembolism in pregnancy and heterotaxy
syndrome has been undertaken along with treatment approach in such situations.
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Heterotaxy is an uncommon polymalformative syndrome
characterized by congenital anomalies that arise from dis-
orderly arrangement of asymmetric thoracic and abdominal
viscera and blood vessels [1]. The estimated prevalence is
approximately 1 in 10,000 live births [2]. Morbidity and
mortality rates are high approaching nearly 70 % due to
major cardiac malformations (especially in heterotaxy with
asplenia patients). Five to ten percent of patients with
minor or no cardiac anomalies will survive to the adulthood
[3–5]. Some will remain asymptomatic and can be diag-
nosed incidentally on imaging studies. Heterotaxy has been
reported to be associated with VTE and is felt to be related* Correspondence: nepperla@mcw.edu
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creativecommons.org/publicdomain/zero/1.0/to abnormal lower extremity venous system [6]. Infact in
the last few years some authors considered it as a VTE risk
factor. However VTE in pregnancy with heterotaxy syn-
drome has not been reported.
Herein we present a case of 26 year-old pregnant female
who suffered cardiac arrest related to massive pulmonary
embolism requiring cardiac resuscitation. Imaging studies
incidentally discovered anatomic variation consistent with
heterotaxy syndrome. She was anticoagulated for 6 months
with low molecular weight heparin (LMWH) and subse-
quently placed on low dose aspirin to prevent recurrent
VTE. A detailed discussion of the pathophysiology of VTE
in pregnancy and heterotaxy syndrome has been under-
taken with a focus on treatment approach in such
situations.rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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A 26 year old otherwise healthy, G1P0 female at 13 weeks
gestation was admitted to medical intensive care unit after
she experienced cardiac arrest at home. She had reported
shortness of breath earlier that day and then collapsed.
During initial paramedic evaluation, she was pulseless and
found to be in pulse less electrical activity (PEA). She was
successfully resuscitated with return of spontaneous circu-
lation (ROSC) in approximately 7 min and was brought to
the hospital. Emergency department (ED) evaluation re-
vealed the patient to be nonresponsive, and she was im-
mediately intubated. Her exam was remarkable for cold
and cyanotic extremities, without palpable distal pulses
but strong femoral pulse. Shortly after her arrival to ED,
the patient became pulse less again needing resuscitation
and ROSC on 2 occasions.
Initial blood work was remarkable for severe metabolic
acidosis (HCO3 of 10) and elevated troponin I (2.77 ng/ml,
normal range 0–0.34 ng/ml). EKG showed right bundle
branch block while bedside 2 D echocardiogram demon-
strated right heart strain pattern. Bedside ultrasound (USG)
showed no significant free fluid with live intrauterine gesta-
tion. Bilateral lower extremity compression venous dopp-
lers of the entire venous system were negative for any
evidence of deep venous thrombosis. She underwent com-
puterized tomography (CT) of the chest which revealed a
nearly occlusive thrombus in the bilateral lower lobar
arteries extending into the segmental arteries (Fig. 1).
The main pulmonary arterial trunk was noted to be en-
larged with evidence of right heart strain (Fig. 2). Head CT
scan was negative for any acute intracranial abnormalities.
She was administered intravenous tissue plasminogen acti-
vator (TPA) (50 mg after ROSC the second time) in the ED
with improvement in her hemodynamics. Hypothermia
protocol was concurrently initiated. She was subsequentlyFig. 1 CT scan of the chest with contrast. The red arrows depict bilateral ntransferred to medical intensive care unit on unfractionated
heparin (UFH), bicarbonate and norepinephrine drips. The
patient was extubated two days following and was gradually
weaned off blood pressure support. UFH drip was titrated
based on aPTT and 6 days later she was transitioned to
LMWH (dalteparin 10,000 units subcutaneously once daily
in view of her insurance issues). She had aggressive
supportive care and after a 2 week hospital stay, she
was discharged to rehabilitation facility on Dalteparin.
A month later dalteparin was changed to enoxaparin
55 mg (1 mg/kg) s/q twice daily (monitored with anti
Xa levels).
At approximately 20 week’s gestation, the patient had a
fetal ultrasound that revealed singleton gestation with
massive hydrops, fetal contractures and ventriculomegaly/
hydranencephaly. It was presumed that these findings
were secondary to early hypoxic injury and she was coun-
seled about poor prognosis. During her 25th week gesta-
tion, the patient noted worsening abdominal pain with
associated headaches, lightheadedness and weakness. She
had elevated blood pressures and was suspected to have
mirror syndrome. Enoxaparin was discontinued 24 h prior
to the planned procedure with initiation of UFH drip. The
patient underwent elective induction of labor with pallia-
tive care services. The infant died shortly after delivery.
The patient experienced increased vaginal bleeding sec-
ondary to retained products of conception and underwent
dilatation and curettage with achievement of hemostasis.
Enoxaparin at previous dosage (55 mg s/q twice daily) was
restarted 24 h after the delivery without any major or un-
toward complication. Platelet count and anti-Xa levels
were checked while the patient was on enoxaparin. Anti-
Xa levels were in therapeutic range (0.8–1, goal 0.6–
1.0 IU/ml) and platelet counts remained within normal
limits.ear occlusive pulmonary emboli
Fig. 2 CT scan of the chest with contrast. The yellow arrow depicts enlarged main pulmonary arterial trunk
Epperla et al. BMC Hematology  (2015) 15:7 Page 3 of 6In order to identify the cause of her VTE the patient had
further work up including thrombophilia testing and CT
chest, abdomen/pelvis. Thrombophilia testing revealed the
patient to be wild type for Factor V and Prothrombin gene.
Protein C and S antigen levels were normal. Antithrombin
activity was initially low (71, normal range 75–125 % ACT)
at the time of initial VTE but subsequently normalized
(107). Antiphospholipid antibody testing including lupus
anticoagulant, anti-cardiolipin antibodies and beta 2 glyco-
protein I antibodies was negative. CT chest, abdomen and
pelvis showed constellation of imaging findings compatible
with heterotaxy syndrome. These included left-sided super-
ior vena cava (SVC) draining into the left coronary sinus,
hemiazygous vein drains into left SVC, absent azygous vein,
absent (interrupted) inferior vena cava (IVC) below the
hepatic IVC with persistent left IVC which drains into left
coronary sinus, polysplenia, bilateral left lung and benign
hepatic hemangioma (Fig. 3A-C).
The patient completed 6 month duration of anticoagu-
lation with LMWH and was subsequently placed on
ASA 81 mg. Prior to discontinuation of anticoagulation
therapy the patient had CT pulmonary angiogram which
showed normal diameter of the main pulmonary artery
without any evidence of acute or chronic pulmonary em-
boli. She is currently stable on low dose ASA and is into
her third year after the VTE without any recurrence. She
has had no further pregnancies.
Discussion
Heterotaxy or situs ambiguous refers to malposition and
dysmorphism of viscera and blood vessels, often with in-
determinate atrial arrangement. This abnormal arrange-
ment of body organs is different from the orderly
arrangement seen in situs solitus or situs inversus. Het-
erotaxy syndrome can be associated with either aspleniaor polysplenia. Our patient had heterotaxy with poly-
splenia and hence will limit our discussion to this abnor-
mality and hereon will be referred to as heterotaxy.
Heterotaxy implies that the patients have bilateral bi-
lobed lungs, bilateral pulmonary atria, a centrally located
liver, a stomach in indeterminate position, interrupted
IVC with azygous continuation and multiple spleens [1].
After polysplenia, the most frequent finding in hetero-
taxy is the hypoplasia of the IVC with absence of the
intrahepatic segment and direct continuation with the
azygous venous system. Heterotaxy commonly occurs as
a sporadic condition but it can be inherited [7].
Varied timing of embryological causative factors dur-
ing the development of fetus can explain the wide range
of anomalies in the heterotaxy syndrome. Cardiac anom-
alies are mostly the result of abnormal embryological de-
velopment around day 28 of embryogenesis, as it is
during this period that connection between primitive
heart and venous channels occurs [8]. The failure of fu-
sion of fetal lobules leads to individualization of multiple
splenic nodules, which are located along the greater
curvature of the stomach, as the spleen develops in the
mesogastric region [9, 10]. IVC is a complex vascular
structure that is developed during weeks 6–8 of embryo-
genesis [11]. During this period three pairs of primitive
venous channels (posterior cardinal, subcardinal and
supracardinal veins) form the mature venous system
(IVC) through a complex sequential process. Various
malformations including partial or even complete ab-
sence of IVC can result from the failure in the develop-
mental steps related to embryonic dysontogenesis that
can affect separate segments or even the entire IVC
[12–14]. Thus mutations in genes that control left-right
patterning and teratogenic exposures in early embryonic
period underlie majority of heterotaxy cases [15].
Fig. 3 A. CT scan of the chest with contrast. Coronal section showing
bilateral bilobed lungs (yellow arrows depict the major fissure). B. CT
scan of the abdomen. The arrow points to multiple splenic lobules
suggestive of polysplenia. C. CT scan of the abdomen. Coronal section
showing azygous continuation of inferior vena cava
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with heterotaxy compared to the general population. It
is postulated that stasis related to the abnormal venous
drainage of the lower extremity venous system due to
interrupted IVC [16, 17] and increased platelet aggrega-
tion related to the anomalous drainage of the splenic
venous system into the azygous system seems to be the
possible culprits for heightened risk of pulmonary
thromboembolism in these patients [9, 18].
VTE is 5 times more frequent in pregnant women than
in non-pregnant women of similar age [19]. This is because
pregnancy induces a state of venous stasis and hypercoagu-
lability from a combination of physical, hormonal and
hematological changes leading to an increased risk for
VTE. Venous stasis occurs from progesterone mediated in-
creased venous distension in the first trimester and the
compressive effect by the enlarging uterus on the common
iliac vein in the late second and third trimesters [20, 21]. In
addition there is an imbalance between the procoagulant
(increased circulating levels of fibrinogen, von Willebrand
factor, VII, VIII, IX, X and XII and increased generation of
fibrin) and anticoagulant factors (decreased Protein S levels
and fibrinolysis) through the pregnancy [19–23]. Though
pregnancy is considered to be a relative contraindication to
systemic thrombolysis (recombinant TPA or streptokinase)
in hemodynamically unstable patients with pulmonary em-
bolism, the risk of complications for pregnant females
treated with thrombolytic agents may be similar to that in
the non-pregnant population [24].
In our case, the exact etiology for VTE is unclear. It
may be related to pregnancy alone or mechanical factors
from distorted venous system anatomy or a combination
of both. Because the patient’s VTE occurred early in
pregnancy, uterine enlargement is unlikely to have con-
tributed to venous thrombosis. Effects of pregnancy in
heterotaxy have been poorly described.
Challenges to the clinical management of our patient in-
clude the duration of anticoagulation and future pregnancy.
Based on the 2012 American College of Chest Physicians
(ACCP) guidelines, anticoagulation with LMWH is recom-
mended for at least 3 months from the initial pulmonary
embolism and 6 weeks postpartum [25]. In our case, the
patient was into her 3rd month of anticoagulation when
she had induction of labor and delivery; hence the anticoa-
gulation was continued for additional 3 months for a total
of 6 months. Subsequently she was placed on low dose as-
pirin (81 mg) to prevent recurrent VTE (especially given
her heterotaxy syndrome) based on the Warfarin and
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Venous Thromboembolism (ASPIRE) trials as well as the
individual patient data analysis of WARFASA and ASPIRE
trials performed by the INSPIRE Collaboration [26–28].
Currently there is no evidence about the risk of VTE
recurrence and anticoagulation duration in similar patients.
According to the 2012 ACCP guidelines the decision re-
garding the duration of anticoagulation in a patient should
be made after careful evaluation of both the risk of VTE re-
currence and bleeding risk. Given the congenital prothrom-
botic risk factor (interrupted IVC related to heterotaxy
syndrome), severity of the presentation and apparently low
bleeding risk extended anticoagulation treatment with tar-
geted oral anticoagulation maybe a suitable alternative to
aspirin with periodic assessment of the bleeding risk.
Our patient had a massive pulmonary embolism with car-
diac arrest that created a great sense of apprehension both
in the patient and her family regarding future pregnancy.
Unfortunately, there is paucity of data to either support or
refute future pregnancy associated with her condition. Pre-
vious VTE alone is not a contraindication to future preg-
nancy provided anticoagulation is available. However
patients with heterotaxy syndrome and VTE are undoubt-
edly at increased risk of VTE compared to other pregnant
women. Hence future pregnancies in this patient group
should be considered high-risk, and requires multi-
disciplinary management. We recommend full intensity
anticoagulation with LMWH (likely enoxaparin 1 mg/kg
two times daily) with regular monitoring of anti-Xa levels
prior to her pregnancy. It is important to measure anti-Xa
levels 4 h after the last dose and be aware of the different
targets based on which LMWH regimen is used (once-daily
[goal 1.0–2.0 IU/mL] or twice-daily [goal 0.6–1 IU/mL]). In
addition we recommend that there is a detailed discussion
between the physician and the patient regarding the role of
thrombolytic therapy in the event of recurrent VTE and
possible termination of pregnancy in the worst case
scenario.
Conclusion
To our knowledge this is the first reported case in the
English literature that shows pregnancy associated VTE
in a person with heterotaxy. After completion of antic-
oagulation therapy for the initial thrombotic event, the
patient needs secondary prevention for VTE recurrence
and low dose aspirin was the chosen treatment in this
case. Although there are no published guidelines we be-
lieve that there are no contraindications for future preg-
nancy in this special group provided the patient is on
anticoagulation prior to the pregnancy.
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